CIENCIASMEDICASNEWS: FDA approves Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy for first-line esophageal squamous cell carcinoma indications | FDA

miércoles, 1 de junio de 2022

FDA approves Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy for first-line esophageal squamous cell carcinoma indications | FDA

FDA approves Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy for first-line esophageal squamous cell carcinoma indications | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)